Evaluation of CD69 as a prognostic factor and its relation with other prognosticatos in a sample of Iraqi patients with chronic lymphocytic leukemia
Chronic lymphocytic leukeamia (CLL) is clinically heterogenous disease with variable prognosis . It is important to take into consideration the prognosis of presenting with CLL before starting suitable therapeutic option. Different studies proved that leukemic CLL cells have the surface membrane phenotype of activated and antigen experienced B lymphocytes with the overexpression of the activation markers such as CD69 . In one previous study, CD69 was assumed to be considered as a new promising immunologic prognostic factor in B-CLL. Aim: In this study we aimed to detect CD69 expression in newly diagnosed patients with CLL by flow cytometry and correlate it with some other clinical and laboratory parameters in order to evaluate its role as a prognostic factor. Patients and Methods: CD69 expression was investigated by flow cytometry in 26 untreated newly diagnosed patients with chronic lymphocytic leukaemia ,and compared this with other standard prognostic parameters (β2- microglobulin , lymphocyte count , Rai stage and CD38 ). Results: The present study shows that about (34. 61% )of the CLL patient were positive for CD69 expression , while (65,38%) of patient were negative. CD69 expression is significantly associated with CD38 (P-0.002), Rai stages (p-0.0001) , lymphocyte count(p-0.0001) , β2-microglobulin (P-0.012). Conclusion: The results of this study demonstrated that CD69 is significantly associated with poor prognostic factors . This supports its introduction in a laboratory assessment of newly diagnosed patient with CLL and, possibly, in a prognostic scoring system for chronic lymphocytic leukemia.